Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Blood (2019) 134 (Supplement_1): 831.

https://doi.org/10.1182/blood-2019-126065

Published: 2019

Journal Articles

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

Blood (2018) 132 (Supplement 1): 4054.

https://doi.org/10.1182/blood-2018-99-116608

Published: 2018

Journal Articles

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Matthew C. Foster, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Benjamin G. Vincent, MD, Melissa Matson, AGPCNP-BC, Karen McKinnon, PhD, Shannon Reisdorf, BS, Jack Zhang, RN, Will Pulley, BA, Hyman Muss, MD, Anastasia Ivanova, PhD, Joshua F Zeidner, MD

Blood (2017) 130 (Supplement 1): 2631.

https://doi.org/10.1182/blood.V130.Suppl_1.2631.2631

Published: 2017

Journal Articles

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2016) 128 (22): 2820.

https://doi.org/10.1182/blood.V128.22.2820.2820

Published: 2016

Journal Articles

A Comparison of Clofarabine-Based (GCLAC) and Cladribine-Based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML

Benyam Muluneh, PharmD, Katie Buhlinger, Allison M. Deal, MS, Joshua F. Zeidner, MD, Matthew C. Foster, MD, Katarzyna Joanna Jamieson, MD, Jill Bates, PharmD, Hendrik W. Van Deventer, MD

Blood (2015) 126 (23): 1342.

https://doi.org/10.1182/blood.V126.23.1342.1342

Published: 2015

Journal Articles

A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Ben A. Blomberg, MD, Hendrik W. Van Deventer, MD, Stuart Gold, MD, Katarzyna Joanna Jamieson, MD, Joshua F. Zeidner, MD, Benyam Muluneh, PharmD, Dominic Moore, PhD, Matthew C. Foster, MD

Blood (2015) 126 (23): 4919.

https://doi.org/10.1182/blood.V126.23.4919.4919

Published: 2015

Journal Articles

The Contribution of Fibrocytes to the Progression of Multiple Myeloma

Hendrik W. van Deventer, MD MS, Peter M. Voorhees, MD, Jonathan S Serody, MD

Blood (2014) 124 (21): 3411.

https://doi.org/10.1182/blood.V124.21.3411.3411

Published: 2014

Journal Articles

Erythroid Differentiation Regulator 1 (ERDR1) From Nurse-Like Cells Promotes the Survival of Chronic Lymphocytic Leukemia Cells

Hendrik W. Van Deventer, MD, MS, Robert Mango, Jonathan Serody, MD

Blood (2010) 116 (21): 1372.

https://doi.org/10.1182/blood.V116.21.1372.1372

Published: 2010

Journal Articles

Pulmonary Stromal Cells Expressing CC-Chemokine Receptor 5 Promote Metastasis Via Erythroid Differentiation Regulator 1.

Robert L Mango, Hendrik W van Deventer, MD, Qing Ping Wu, Jonathan S Serody, MD, PhD

Blood (2009) 114 (22): 3601.

https://doi.org/10.1182/blood.V114.22.3601.3601

Published: 2009

Journal Articles

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

C Foster Matthew, MD, Chirag Amin, MD, Peter M Voorhees, MD, Hendrik W. Van Deventer, MD, Kristy L. Richards, PhD, MD, Anastasia Ivanova, Jennifer Whitman, RN, BSN, Thomas C. Shea, MD

Blood (2009) 114 (22): 2048.

https://doi.org/10.1182/blood.V114.22.2048.2048

Published: 2009

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

Journal Articles

A Systematic Review Evaluating the Addition of Radiation Therapy to Chemotherapy for Localized Aggressive Non-Hodgkin’s Lymphoma: What Is the Role for Radiotherapy?.

Daniel B. Fried, MD, PhD, David E. Morris, MD, Thomas C. Shea, MD, Robert Z. Orlowski, MD, PhD, Hendrik W. Van Deventer, MD, Beverly S. Mitchell, MD

Blood (2004) 104 (11): 3155.

https://doi.org/10.1182/blood.V104.11.3155.3155

Published: 2004

NARROW

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML

Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)

A Comparison of Clofarabine-Based (GCLAC) and Cladribine-Based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML

A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

The Contribution of Fibrocytes to the Progression of Multiple Myeloma

Erythroid Differentiation Regulator 1 (ERDR1) From Nurse-Like Cells Promotes the Survival of Chronic Lymphocytic Leukemia Cells

Pulmonary Stromal Cells Expressing CC-Chemokine Receptor 5 Promote Metastasis Via Erythroid Differentiation Regulator 1.

A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML).

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

A Systematic Review Evaluating the Addition of Radiation Therapy to Chemotherapy for Localized Aggressive Non-Hodgkin’s Lymphoma: What Is the Role for Radiotherapy?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only